MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318657 | Name: Remikiren

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Remikiren is an orally active, high specificity Renin inhibitor used for the treatment of hypertension and high blood pressure.

Chemical Structure

Remikiren
Remikiren
CAS#126222-34-2

Theoretical Analysis

MedKoo Cat#: 318657

Name: Remikiren

CAS#: 126222-34-2

Chemical Formula: C33H50N4O6S

Exact Mass: 630.3451

Molecular Weight: 630.84

Elemental Analysis: C, 62.83; H, 7.99; N, 8.88; O, 15.22; S, 5.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Remikiren; CHEMBL31601; AC1O44IV; 126222-34-2; C07465; D09038; Ro 42-5892; Ro-42-5892;
IUPAC/Chemical Name
(2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide
InChi Key
UXIGZRQVLGFTOU-UHFFFAOYSA-N
InChi Code
InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)
SMILES Code
CC(C)(C)S(=O)(=O)CC(CC1=CC=CC=C1)C(=O)NC(CC2=CN=CN2)C(=O)NC(CC3CCCCC3)C(C(C4CC4)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 630.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: van Paassen P, de Zeeuw D, Navis G, de Jong PE. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant. 2000 May;15(5):637-43. PubMed PMID: 10809804. 2: Himmelmann A, Bergbrant A, Svensson A, Hansson L, Aurell M. Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am J Hypertens. 1996 Jun;9(6):517-22. PubMed PMID: 8783774. 3: Richter WF, Whitby BR, Chou RC. Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Xenobiotica. 1996 Mar;26(3):243-54. PubMed PMID: 8730917. 4: Kleinbloesem CH, Weber C, Fahrner E, Dellenbach M, Welker H, Schröter V, Belz GG. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Ther. 1993 May;53(5):585-92. PubMed PMID: 8491068. 5: Clozel JP, Fischli W. Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung. 1993 Feb;43(2A):260-2. Review. PubMed PMID: 8498974. 6: van Kats JP, Sassen LM, Danser AH, Polak MP, Soei LK, Derkx FH, Schalekamp MA, Verdouw PD. Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren. Br J Pharmacol. 1996 Mar;117(5):891-901. PubMed PMID: 8851507; PubMed Central PMCID: PMC1909430. 7: Coassolo P, Fischli W, Clozel JP, Chou RC. Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. Xenobiotica. 1996 Mar;26(3):333-45. PubMed PMID: 8730924. 8: Jauch R, Schmid P, Fischli W, Meister W, Maurer R, Wendt G. Excretion and metabolism of remikiren, a potent orally active inhibitor of primate renin. Xenobiotica. 1996 Mar;26(3):285-95. PubMed PMID: 8730920. 9: van Paassen P, de Zeeuw D, de Jong PE. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. J Cardiovasc Pharmacol. 1995 Jul;26(1):39-45. PubMed PMID: 7564363. 10: MacFadyen RJ, Jones CR, Doig JK, Birnbock H, Reid JL. Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans. J Cardiovasc Pharmacol. 1995 Mar;25(3):347-53. PubMed PMID: 7769797. 11: Hilgers KF, Fischli W, Veelken R, Mann JF. Vascular renin in the guinea pig. Suppression by the renin inhibitor remikiren. Hypertension. 1994 Jun;23(6 Pt 2):861-4. PubMed PMID: 8206619. 12: Weber C, Birnböck H, Leube J, Kobrin I, Kleinbloesem CH, Van Brummelen P. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. Br J Clin Pharmacol. 1993 Dec;36(6):547-54. PubMed PMID: 12959271; PubMed Central PMCID: PMC1364659.